RSS-Feed abonnieren
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0038-1646924
Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia
Funding Research by the group of F.F.-M. and J.R. is supported by grants from Instituto de Salud Carlos III and Feder (PI14/01956) and Fundación Séneca (19873/GERM/15). V.P.-B. holds a research fellowship from CIBERER (CB15/00055). Research by the group of S.P.W. is supported by the British Heart Foundation (RG/ PG/13/36/30275; RG/09/007).Publikationsverlauf
16. Januar 2018
01. April 2018
Publikationsdatum:
25. April 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/201806/lookinside/thumbnails/10-1055-s-0038-1646924_180042-1.jpg)
Abstract
Neonatal platelets are hypo-reactive to the tyrosine kinase-linked receptor agonist collagen. Here, we have investigated whether the hypo-responsiveness is related to altered levels of glycoprotein VI (GPVI) and integrin α2β1, or to defects in downstream signalling events by comparison to platelet activation by C-type lectin-like receptor 2 (CLEC-2). GPVI and CLEC-2 activate a Src- and Syk-dependent signalling pathway upstream of phospholipase C (PLC) γ2. Phosphorylation of a conserved YxxL sequence known as a (hemi) immunotyrosine-based-activation-motif (ITAM) in both receptors is critical for Syk activation. Platelets from human pre-term and full-term neonates display mildly reduced expression of GPVI and CLEC-2, as well as integrin αIIbβ3, accounted for at the transcriptional level. They are also hypo-responsive to the two ITAM receptors, as shown by measurement of integrin αIIbβ3 activation, P-selectin expression and Syk and PLCγ2 phosphorylation. Mouse platelets are also hypo-responsive to GPVI and CLEC-2 from late gestation to 2 weeks of age, as determined by measurement of integrin αIIbβ3 activation. In contrast, the response to G protein-coupled receptor agonists was only mildly reduced and in some cases not altered in neonatal platelets of both species. A reduction in response to GPVI and CLEC-2, but not protease-activated receptor 4 (PAR-4) peptide, was also observed in adult mouse platelets following immune thrombocytopenia, whereas receptor expression was not impaired. Our results demonstrate developmental differences in platelet responsiveness to GPVI and CLEC-2, and also following immune platelet depletion leading to reduced Syk activation. The rapid generation of platelets during development or following platelet depletion is achieved at the expense of signalling by ITAM-coupled receptors.
Keywords
premature - full-term neonates - platelet hypo-responsiveness - ITAM-containing receptors - development - immune-induced thrombocytopenia-
References
- 1 Thomas MR, Storey RF. The role of platelets in inflammation. Thromb Haemost 2015; 114 (03) 449-458
- 2 Middleton E, Rondina MT. Platelets in infectious disease. Hematology (Am Soc Hematol Educ Program) 2016; 2016 (01) 256-261
- 3 Lee RH, Bergmeier W. Platelet immunoreceptor tyrosine-based activation motif (ITAM) and hemITAM signaling and vascular integrity in inflammation and development. J Thromb Haemost 2016; 14 (04) 645-654
- 4 Lowe KL, Finney BA, Deppermann C. , et al. Podoplanin and CLEC-2 drive cerebrovascular patterning and integrity during development. Blood 2015; 125 (24) 3769-3777
- 5 Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011; 11 (02) 123-134
- 6 Jilma-Stohlawetz P, Homoncik M, Jilma B. , et al. High levels of reticulated platelets and thrombopoietin characterize fetal thrombopoiesis. Br J Haematol 2001; 112 (02) 466-468
- 7 Liu ZJ, Hoffmeister KM, Hu Z. , et al. Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan. Blood 2014; 123 (22) 3381-3389
- 8 Wolber FM, Leonard E, Michael S, Orschell-Traycoff CM, Yoder MC, Srour EF. Roles of spleen and liver in development of the murine hematopoietic system. Exp Hematol 2002; 30 (09) 1010-1019
- 9 Hézard N, Potron G, Schlegel N, Amory C, Leroux B, Nguyen P. Unexpected persistence of platelet hyporeactivity beyond the neonatal period: a flow cytometric study in neonates, infants and older children. Thromb Haemost 2003; 90 (01) 116-123
- 10 Israels SJ, Rand ML, Michelson AD. Neonatal platelet function. Semin Thromb Hemost 2003; 29 (04) 363-372
- 11 Sola-Visner M. Platelets in the neonatal period: developmental differences in platelet production, function, and hemostasis and the potential impact of therapies. Hematology (Am Soc Hematol Educ Program) 2012; 2012: 506-511
- 12 Tesfamariam B. Distinct characteristics of neonatal platelet reactivity. Pharmacol Res 2017; 123: 1-9
- 13 Israels SJ, Daniels M, McMillan EM. Deficient collagen-induced activation in the newborn platelet. Pediatr Res 1990; 27 (4 Pt 1): 337-343
- 14 Saxonhouse MA, Sola MC. Platelet function in term and preterm neonates. Clin Perinatol 2004; 31 (01) 15-28
- 15 Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor?. Blood 2003; 102 (02) 449-461
- 16 Gelman B, Setty BN, Chen D, Amin-Hanjani S, Stuart MJ. Impaired mobilization of intracellular calcium in neonatal platelets. Pediatr Res 1996; 39 (4 Pt 1): 692-696
- 17 Corby DG, O'Barr TP. Decreased alpha-adrenergic receptors in newborn platelets: cause of abnormal response to epinephrine. Dev Pharmacol Ther 1981; 2 (04) 215-225
- 18 Schlagenhauf A, Schweintzger S, Birner-Gruenberger R, Leschnik B, Muntean W. Newborn platelets: lower levels of protease-activated receptors cause hypoaggregability to thrombin. Platelets 2010; 21 (08) 641-647
- 19 Sitaru AG, Holzhauer S, Speer CP. , et al. Neonatal platelets from cord blood and peripheral blood. Platelets 2005; 16 (3-4): 203-210
- 20 Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008; 371 (9606): 75-84
- 21 Setzer ES, Webb IB, Wassenaar JW, Reeder JD, Mehta PS, Eitzman DV. Platelet dysfunction and coagulopathy in intraventricular hemorrhage in the premature infant. J Pediatr 1982; 100 (04) 599-605
- 22 Josephson CD, Granger S, Assmann SF. , et al. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood 2012; 120 (04) 748-760
- 23 Navarro-Núñez L, Langan SA, Nash GB, Watson SP. The physiological and pathophysiological roles of platelet CLEC-2. Thromb Haemost 2013; 109 (06) 991-998
- 24 Gitz E, Pollitt AY, Gitz-Francois JJ. , et al. CLEC-2 expression is maintained on activated platelets and on platelet microparticles. Blood 2014; 124 (14) 2262-2270
- 25 Hughes CE, Pollitt AY, Mori J. , et al. CLEC-2 activates Syk through dimerization. Blood 2010; 115 (14) 2947-2955
- 26 Caparrós-Pérez E, Teruel-Montoya R, López-Andreo MJ. , et al. Comprehensive comparison of neonate and adult human platelet transcriptomes. PLoS One 2017; 12 (08) e0183042
- 27 Mazharian A, Thomas SG, Dhanjal TS, Buckley CD, Watson SP. Critical role of Src-Syk-PLCgamma2 signaling in megakaryocyte migration and thrombopoiesis. Blood 2010; 116 (05) 793-800
- 28 Gibbins JM, Okuma M, Farndale R, Barnes M, Watson SP. Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain. FEBS Lett 1997; 413 (02) 255-259
- 29 Tsuji M, Ezumi Y, Arai M, Takayama H. A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J Biol Chem 1997; 272 (38) 23528-23531
- 30 Carsetti L, Laurenti L, Gobessi S, Longo PG, Leone G, Efremov DG. Phosphorylation of the activation loop tyrosines is required for sustained Syk signaling and growth factor-independent B-cell proliferation. Cell Signal 2009; 21 (07) 1187-1194
- 31 Watanabe D, Hashimoto S, Ishiai M. , et al. Four tyrosine residues in phospholipase C-gamma 2, identified as Btk-dependent phosphorylation sites, are required for B cell antigen receptor-coupled calcium signaling. J Biol Chem 2001; 276 (42) 38595-38601
- 32 Ferrer-Marin F, Stanworth S, Josephson C, Sola-Visner M. Distinct differences in platelet production and function between neonates and adults: implications for platelet transfusion practice. Transfusion 2013; 53 (11) 2814-2821
- 33 Lorenz V, Ramsey H, Liu ZJ. , et al. Developmental stage-specific manifestations of absent TPO/c-MPL signalling in newborn mice. Thromb Haemost 2017; 117 (12) 2322-2333
- 34 Baker-Groberg SM, Lattimore S, Recht M, McCarty OJ, Haley KM. Assessment of neonatal platelet adhesion, activation, and aggregation. J Thromb Haemost 2016; 14 (04) 815-827
- 35 Gupta S, Cherpokova D, Spindler M, Morowski M, Bender M, Nieswandt B. GPVI signaling is compromised in newly formed platelets after acute thrombocytopenia in mice. Blood 2018; 131 (10) 1106-1110
- 36 Alter BP. Fetal erythropoiesis in stress hematopoiesis. Exp Hematol 1979; 7 (Suppl. 05) 200-209
- 37 Link MP, Alter BP. Fetal-like erythropoiesis during recovery from transient erythroblastopenia of childhood (TEC). Pediatr Res 1981; 15 (07) 1036-1039
- 38 Weinberg RS, Schofield JM, Lenes AL, Brochstein J, Alter BP. Adult ‘fetal-like’ erythropoiesis characterizes recovery from bone marrow transplantation. Br J Haematol 1986; 63 (03) 415-424
- 39 Caparrós-Pérez E, Teruel-Montoya R, Palma-Barquero V. , et al. Down regulation of the Munc18b-syntaxin-11 complex and β1-tubulin impairs secretion and spreading in neonatal platelets. Thromb Haemost 2017; 117 (11) 2079-2091
- 40 Stolla MCLK, Catherman SC, McGrath KE, Palis J. P-selectin expression and platelet function are developmentally regulated. Blood 2014; 124 (21) 1439-1439
- 41 Lockyer S, Okuyama K, Begum S. , et al. GPVI-deficient mice lack collagen responses and are protected against experimentally induced pulmonary thromboembolism. Thromb Res 2006; 118 (03) 371-380
- 42 Margraf A, Nussbaum C, Rohwedder I. , et al. Maturation of platelet function during murine fetal development in vivo. Arterioscler Thromb Vasc Biol 2017; 37 (06) 1076-1086
- 43 Ferrer-Marin F, Chavda C, Lampa M, Michelson AD, Frelinger III AL, Sola-Visner M. Effects of in vitro adult platelet transfusions on neonatal hemostasis. J Thromb Haemost 2011; 9 (05) 1020-1028
- 44 Ugorski M, Dziegiel P, Suchanski J. Podoplanin - a small glycoprotein with many faces. Am J Cancer Res 2016; 6 (02) 370-386
- 45 Astarita JL, Acton SE, Turley SJ. Podoplanin: emerging functions in development, the immune system, and cancer. Front Immunol 2012; 3: 283
- 46 Williams MC, Cao Y, Hinds A, Rishi AK, Wetterwald A. T1 alpha protein is developmentally regulated and expressed by alveolar type I cells, choroid plexus, and ciliary epithelia of adult rats. Am J Respir Cell Mol Biol 1996; 14 (06) 577-585
- 47 Wang Y, Sun J, Gu Y, Zhao S, Groome LJ, Alexander JS. D2-40/podoplanin expression in the human placenta. Placenta 2011; 32 (01) 27-32
- 48 Stanworth SJ. Thrombocytopenia, bleeding, and use of platelet transfusions in sick neonates. Hematology (Am Soc Hematol Educ Program) 2012; 2012: 512-516
- 49 Kenet G, Kuperman AA, Strauss T, Brenner B. Neonatal IVH--mechanisms and management. Thromb Res 2011; 127 (3, Suppl 3) S120-S122
- 50 Monagle P, Chan AKC, Goldenberg NA. , et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e737S-e801S